Utvalda publikationer från OnkPat

This page in English

Publikationer från OnkPat med impact factor 8 och högre:


4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.
Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al
Ann. Oncol. 2018 Aug;29(8):1634-1657

PD-L1+ tumor-associated macrophages and PD-1+ tumor infiltrating lymphocytes predict survival in primary testicular lymphoma.
Pollari M, Brück O, Pellinen T, Vähämurto P, Karjalainen-Lindsberg M, Mannisto S, et al
Haematologica 2018 Jul;():

An orthotopic glioblastoma animal model suitable for high-throughput screenings.
Pudelko L, Edwards S, Balan M, Nyqvist D, Al-Saadi J, Dittmer J, et al
Neuro-oncology 2018 Oct;20(11):1475-1484

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.
Pagès F, Mlecnik B, Marliot F, Bindea G, Ou F, Bifulco C, et al
Lancet 2018 May;391(10135):2128-2139

A coding and non-coding transcriptomic perspective on the genomics of human metabolic disease.
Timmons J, Atherton P, Larsson O, Sood S, Blokhin I, Brogan R, et al
Nucleic Acids Res. 2018 Sep;46(15):7772-7792

Novel Multiomics Profiling of Human Carotid Atherosclerotic Plaques and Plasma Reveals Biliverdin Reductase B as a Marker of Intraplaque Hemorrhage.
Matic L, Jesus Iglesias M, Vesterlund M, Lengquist M, Hong M, Saieed S, et al
JACC Basic Transl Sci 2018 Aug;3(4):464-480

Emergence and evolution of mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide.
Lodé L, Ménard A, Flet L, Richebourg S, Loirat M, Eveillard M, et al
Haematologica 2018 Apr;103(4):e143-e146

Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple alterations.
Lodé L, Ameur A, Coste T, Ménard A, Richebourg S, Gaillard J, et al
Haematologica 2018 Jan;103(1):e13-e16

Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML.
Brück O, Blom S, Dufva O, Turkki R, Chheda H, Ribeiro A, et al
Leukemia 2018 Jul;32(7):1643-1656

Reduced Expression of PROX1 Transitions Glioblastoma Cells into a Mesenchymal Gene Expression Subtype.
Goudarzi K, Espinoza J, Guo M, Bartek J, Nistér M, Lindström M, et al
Cancer Res. 2018 Oct;78(20):5901-5916

Modulation of Protein-Interaction States through the Cell Cycle.
Dai L, Zhao T, Bisteau X, Sun W, Prabhu N, Lim Y, et al
Cell 2018 May;173(6):1481-1494.e13

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.
Malcikova J, Tausch E, Rossi D, Sutton L, Soussi T, Zenz T, et al
Leukemia 2018 May;32(5):1070-1080

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
Curigliano G, Burstein H, Winer E, Gnant M, Dubsky P, Loibl S, et al
Ann. Oncol. 2018 May;():

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.
Azimi A, Caramuta S, Seashore-Ludlow B, Boström J, Robinson J, Edfors F, et al
Mol. Syst. Biol. 2018 03;14(3):e7858

Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.
Björklund A, Carlsten M, Sohlberg E, Liu L, Clancy T, Karimi M, et al
Clin. Cancer Res. 2018 Apr;24(8):1834-1844

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines.
Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, et al
Ann. Oncol. 2018 Oct;29(Supplement_4):iv96-iv110

Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.
Mundt F, Rajput S, Li S, Ruggles K, Mooradian A, Mertins P, et al
Cancer Res. 2018 May;78(10):2732-2746

Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy.
Stafford W, Peng X, Olofsson M, Zhang X, Luci D, Lu L, et al
Sci Transl Med 2018 Feb;10(428):

Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells.
Page B, Valerie N, Wright R, Wallner O, Isaksson R, Carter M, et al
Nat Commun 2018 01;9(1):250

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Cats A, Jansen E, van Grieken N, Sikorska K, Lind P, Nordsmark M, et al
Lancet Oncol. 2018 May;19(5):616-628

First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells.
Hojjat-Farsangi M, Daneshmanesh A, Khan A, Shetye J, Mozaffari F, Kharaziha P, et al
Leukemia 2018 Oct;32(10):2291-2295

Integrated multi-omic analysis of host-microbiota interactions in acute oak decline.
Broberg M, Doonan J, Mundt F, Denman S, McDonald J
Microbiome 2018 01;6(1):21

Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma.
Ren W, Ye X, Su H, Li W, Liu D, Pirmoradian M, et al
Blood 2018 Jun;131(24):2670-2681

Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA induce myeloid malignancies via unique SNP-specific RNA mutations.
Shah M, Ferracin M, Pileczki V, Chen B, Redis R, Fabris L, et al
Genome Res. 2018 04;28(4):432-447

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.
Galluzzi L, Vitale I, Aaronson S, Abrams J, Adam D, Agostinis P, et al
Cell Death Differ. 2018 Mar;25(3):486-541

Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing.
Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, et al
Cell 2018 May;173(4):879-893.e13

Circadian organization of the genome.
Mallet de Lima C, Göndör A
Science 2018 03;359(6381):1212-1213

Goserelin does not preserve ovarian function against chemotherapy-induced damage.
Oktay K, Taylan E, Rodriguez-Wallberg K, Bedoschi G, Turan V, Pacheco F
Ann. Oncol. 2018 Feb;29(2):512-513

Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.
Sveen A, Bruun J, Eide P, Eilertsen I, Ramirez L, Murumägi A, et al
Clin. Cancer Res. 2018 Feb;24(4):794-806

Discovery of coding regions in the human genome by integrated proteogenomics analysis workflow.
Zhu Y, Orre L, Johansson H, Huss M, Boekel J, Vesterlund M, et al
Nat Commun 2018 03;9(1):903

Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach.
Bereczki E, Branca R, Francis P, Pereira J, Baek J, Hortobágyi T, et al
Brain 2018 Feb;141(2):582-595

A Common Peptidolytic Mechanism for Targeting Peptide Degradation in Mitochondria and Chloroplasts.
Kmiec B, Branca R, Murcha M, Lehtiö J, Glaser E, Teixeira P
Mol Plant 2018 Feb;11(2):342-345

Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes.
Ullah I, Karthik G, Alkodsi A, Kjällquist U, Stålhammar G, Lövrot J, et al
J. Clin. Invest. 2018 Apr;128(4):1355-1370

Erectile Function and Oncologic Outcomes Following Open Retropubic and Robot-assisted Radical Prostatectomy: Results from the LAParoscopic Prostatectomy Robot Open Trial.
Sooriakumaran P, Pini G, Nyberg T, Derogar M, Carlsson S, Stranne J, et al
Eur. Urol. 2018 04;73(4):618-627

Driving Protein Conformational Changes with Light: Photoinduced Structural Rearrangement in a Heterobimetallic Oxidase.
Maugeri P, Griese J, Branca R, Miller E, Smith Z, Eirich J, et al
J. Am. Chem. Soc. 2018 01;140(4):1471-1480

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
Andersson E, Pützer S, Yadav B, Dufva O, Khan S, He L, et al
Leukemia 2018 Mar;32(3):774-787

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.
Parker C, Coleman R, Sartor O, Vogelzang N, Bottomley D, Heinrich D, et al
Eur. Urol. 2017 Jul;():

-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling.
Dzieran J, Rodriguez Garcia A, Westermark U, Henley A, Eyre Sánchez E, Träger C, et al
Proc. Natl. Acad. Sci. U.S.A. 2018 02;115(6):E1229-E1238

Targeting mutant p53 for efficient cancer therapy.
Bykov V, Eriksson S, Bianchi J, Wiman K
Nat. Rev. Cancer 2018 Feb;18(2):89-102

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.

Lancet Oncol. 2018 Jan;19(1):27-39

Polysome-profiling in small tissue samples.
Liang S, Bellato H, Lorent J, Lupinacci F, Oertlin C, van Hoef V, et al
Nucleic Acids Res. 2018 Jan;46(1):e3

Risk of Acute Testicular Failure After Preoperative Radiotherapy for Rectal Cancer: A Prospective Cohort Study.
Buchli C, Martling A, Abani M, Frödin J, Bottai M, Lax I, et al
Ann. Surg. 2018 Feb;267(2):326-331